What the FDA labels say about taking them together
Acetazolamide and topiramate
Topiramate's FDA label of June 1, 2026 names acetazolamide in its drug interactions section; the acetazolamide label PlainMeds reads does not name topiramate. The topiramate label: “Concomitant use of EPRONTIA, a carbonic anhydrase inhibitor, with any other carbonic anhydrase inhibitor may increase the severity of metabolic acidosis and may also increase the risk of kidney stone formation.”
Check it at the source: the acetazolamide FDA label on DailyMed (effective August 19, 2026, Strides Pharma Science Limited); the topiramate FDA label on DailyMed (effective June 1, 2026, Sun Pharmaceutical Industries, Inc.).
What does the acetazolamide label say about topiramate?
Acetazolamide's label (effective August 19, 2026) does not name topiramate in these sections. A label lists what its studies and reports found; it is not a complete list.
Source: FDA drug label (Acetazolamide), Strides Pharma Science Limited, effective August 19, 2026 (SPL set 4813b9dd-5f58-44bb-ad64-cdb331828080), via openFDA; the full label on DailyMed
What does the topiramate label say about acetazolamide?
Topiramate label, drug interactionsConcomitant use of topiramate, a carbonic anhydrase inhibitor, with any other carbonic anhydrase inhibitor (e.g., zonisamide or acetazolamide) may increase the severity of metabolic acidosis and may also increase the risk of kidney stone formation.
Source: FDA drug label (Eprontia, NDA214679), Azurity Pharmaceuticals, Inc., effective November 13, 2025 (SPL set e2a4df59-fead-4a01-9021-9eda02c48010), via openFDA
Source: FDA drug label (Topiramate), Sun Pharmaceutical Industries, Inc., effective June 1, 2026 (SPL set 3c909a53-ae66-4b28-a741-b60bb25a69cf), via openFDA; the full label on DailyMed
These are the labels' own sentences. PlainMeds does not grade interactions; a pharmacist or prescriber can say what they mean for one person's medicines.
Both medicines on the record
| Acetazolamide | Topiramate | |
|---|---|---|
| Labeled for | n/a | Seizures and epilepsy, Migraine |
| Boxed warning | No | No |
| Pharmacy cost (NADAC) | $0.134 per tablet 250 mg tablet | $0.0567 per tablet 100 mg tablet |
| Shortage now | No current entry | No current entry |
Source: FDA NDC Directory, CMS NADAC of October 7, 2026 and the FDA Drug Shortage Database (FDA files October 8, 2026)
What next?
- Check more medicines together
- up to five at once